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Abstract: Background Crohn’s disease (CD) may progress from an inflammatory to a stricturing or
penetrating disease phenotype. The aim of our study was to identify single nucleotide polymorphisms
(SNPs) that predict disease progression in patients of the Swiss IBD Cohort Study (SIBDCS). Methods
We applied a multi-state Markov model for progression behavior of CD with three behavioral states
according to the Montreal classification. The model considered transition from B1 to B2/B3 or from
B2 to B3 stage. Model dynamics were summarized with transition intensities by including the effect of
SNPs and calculating transition intensities for each SNP. Results We included 1276 CD patients [669
(52.4%) B1, 248 (19.4%) B2, 359 (28.1%) B3 patients] with a median follow-up of 6.8 (interquartile range
= 3.6-9.1; range 0-11.6) years. Probability for a B1 patient to develop a stenosis (B1 to B2, q = 0.033)
was twice as much as compared to developing a penetrating complication (B3) during the disease course.
In contrast, the probability of entering B3 stage was similar regardless of whether antecedent stricture
was present (B2 to B3, q = 0.016) or not (B1 to B3, q = 0.016). We identified SNPs within the gene loci
encoding ZMIZ1, LOC105373831 and KSR1 as carrying the highest risk for progression to B3, while the
presence of SNPs within gene loci TNFSF15 and CEBPB-PTPN1 protected from progression to B2 or
B3. Conclusion We identified new genetic risk factors that can predict disease course in CD patients. A
closer understanding on the functional impact of these genetic variations might improve our treatment
options finally to prevent disease progression in CD patients.
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Introduction
Crohn’s disease (CD) affects about one out of 
200 people in developed countries with rising 
incidence and prevalence, often involving lifelong 
debilitating symptoms.1,2 Although at initial diag-
nosis the majority of inflammatory bowel disease 
(IBD) patients have a purely inflammatory dis-
ease, during their disease course, more than 50% 
of patients finally develop a stricturing or pene-
trating disease,3–5 corresponding to a progression 
in the B stage according to the Montreal 
classification.4
At the beginning of the anti-tumor necrosis factor 
(TNF) era it was found that over a 5-year period 
10% of patients progress from an inflammatory to 
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a stricturing disease and 26% of patients progress 
to a penetrating disease phenotype.4 However, 
recent studies estimate the number of patients 
with a progression to penetrating disease behavior 
over time to be smaller, while other studies did not 
detect an effect of biological or immunosuppres-
sive medications on progression to B3 stage.6–8 
However, contradictory data from The 
Netherlands suggested that disease progression 
(B-stage progression) in CD patients is still unal-
tered and not affected by biological or immuno-
suppressive medications.9
Knowledge about the factors driving the disease 
progression from an inflammatory to a stricturing 
or penetrating disease phenotype and the result-
ing onset of long-term complications is crucial. 
Clinical parameters, such as the initial CD loca-
tion at diagnosis, smoking and the age of the 
patient at diagnosis, have been established as risk 
factors for a progression to B stage.3,4,10–14
Genetic risk factors for the development of pene-
trating CD include African American origin and 
family history.15 In addition, it has been demon-
strated that host genetics and particularly the 
presence of specific single nucleotide polymor-
phisms (SNPs) within IBD risk genes critically 
impact the pathogenesis of CD. Such SNPs have 
also been associated with the development of 
penetrating CD.16 However, these data have not 
been confirmed so far.
Here, we aimed at identifying the impact of spe-
cific genetic risk factors for B-stage progression in 
CD patients using patients from the Swiss IBD 
cohort study (SIBDCS).
Patients and methods
Patient data and cohort design
Demographic and clinical data were obtained from 
the database of the nationwide SIBDCS. The 
SIBDCS represents a Swiss-wide multicenter pro-
spective observational study and includes IBD 
patients from all over Switzerland. The SIBDCS 
study has been continuously funded by the Swiss 
National Science Foundation (SNSF) since 2006. 
Repetitively applying a standardized questionnaire, 
patient data are collected once a year and entered 
into a central database. Therefore, the location of 
the disease according to the Montreal classification 
over time is available for all patients included. 
Comprehensive inclusion and exclusion criteria 
and further details on the SIBDCS are described 
elsewhere.17,18 The SIBDCS has been approved by 
the respective ethical committees in Switzerland 
(Ethics Committee of the Canton Zürich: 
EK-1316). All patients signed an informed consent 
for data collection and analysis for research pur-
poses. The presented study has been evaluated and 
approved by the scientific board of the SIBDCS.
Study design
We investigated genetic risk SNPs for the develop-
ment of penetrating CD (Montreal B3) of SIBDCS 
patients. Genotyping of SIBDC patients for 160 
IBD risk SNPs was performed using Matrix-
assisted laser desorption ionization time of flight 
mass spectrometry (MALDI-TOFF)  mass spec-
trometry as described previously.19 Analyses were 
performed on those 160 SNPs which were known 
as IBD risk SNPs at the time of performing our 
molecular analyses.20 For our study, we included 
1276 CD patients for whom clinical and genetic 
information was available. The median follow-up 
was 6.8 years [interquartile range (IQR) = 3.6–
9.1 years; range 0–11.6 years]. Each SNP was 
coded as follows: “0”, if no risk allele was present, 
“1”, if one risk allele was present (heterozygous), 
“2”, if two risk alleles were present (homozygous).
Calculation of variant allele frequencies
Allele frequencies of variants were calculated 
using the BCFtools software package21 and 
1000Genomes populations genotype data22 
downloaded from http://ftp.1000genomes.ebi.
ac.uk/vol1/ftp/release/20130502/supporting/
GRCh38_positions/. In addition, allele frequency 
information estimated from populations of the 
Haplotype Reference Consortium (HRC) refer-
ence panel was extracted from data provided by 
the Sanger Imputation Server, https://imputa-
tion.sanger.ac.uk and http://www.haplotype-ref-
erence-consortium.org/home.23
Association look-ups with other traits and 
diseases
In order to highlight variants with strong evi-
dence of association with other traits or diseases, 
we queried 13 variants against the PhenoScanner 
database version 224 and extracted information 
about known associations with genome-wide sig-
nificance (p < 5 × 10–8) from published genome 
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wide association studies (GWAS). PhenoScanner 
is a curated database holding publicly available 
results from large-scale genetic association stud-
ies published through the NHGRI-EBI GWAS 
catalogue (https://www.ebi.ac.uk/gwas/), NHLBI 
GRASP (https://grasp.nhlbi.nih.gov/), dbGaP 
catalogues (https://www.ncbi.nlm.nih.gov/gap/) 
and UK Biobank pheWAS by Benjamin Neale 
(http://www.nealelab.is/uk-biobank).
Statistical analysis
We considered a multi-state Markov model for 
progression behavior of CD with three disease 
states according to the Montreal classification of 
CD.25 State B1 represents inflammatory disease 
without the presence of stenosis or fistula, B2 
comprises stenoses but without fistula and B3 
comprises the presence of any kind of fistula with 
or without additional stenosis.
Our model allowed the following transitions 
between the different states: a patient in B1 state 
can either remain in B1, or evolve into either B2 
(develop a stenosis) or alternatively straight into 
B3 (develop a fistula). A patient in B2 state, already 
having a current stenosis or a history thereof, can 
either remain in B2, or evolve into B3 (develop a 
penetrating complication). A patient in B2 cannot 
go back to B1 as B1 is defined as “no history of 
complication (fistula or stenosis)”. A patient in B3 
has already a history of fistula, and can only stay in 
B3. This B3 state is therefore called the “absorbing 
state”, as a patient in B3 will always stay in B3 and 
can never leave this B3 state any more.
To represent the dynamic of the model better, we 
computed the following probabilities: probability of 
a B1 patient staying in B1 state, probability of a B1 
patient ending up in B2, probability of a B1 patient 
ending up in B3 state and probability of a B2 patient 
ending up in B3 state after 1, 5, 10 or 15 years.
For each scenario, the effect of the number of risk 
alleles on the transition intensities was summarized 
with hazard ratios (HRs) with 95% confidence 
interval (CI; HR > 1 indicating higher intensities, 
resulting in more complications; HR < 1 indicating 
lower intensities, resulting in fewer complications). 
Again, in each case, the dynamics of the system 
were illustrated with the probabilities of finally 
having transitioned into (or remained, respectively, 
in the case of sustained B1 stage) in the different B 
stages after 1, 5, 10 or 15 years.
We finally performed two different modelings, a 
linear and a categorical modeling, to demonstrate 
these SNP effects in more detail. First, we investi-
gated the “linear” effect model. Here, the number 
of risk alleles was taken as a continuous variable, 
which forced the effect to be linear. This meant 
that having two risk alleles exerted twice the effect 
of having only one, and going from zero to one risk 
allele was the same effect as going from one allele 
to two. We then performed the “categorical” effect 
model: here the effect of the number of risk alleles 
could be more general. This meant that there was 
more freedom to define the different effects. We 
did not “force” any kind of relationship between 
effects of zero, one or two risk alleles. To this end, 
we put the SNPs into the model and tested if there 
was an overall effect on the transition intensities 
and analyzed the significant SNPs in detail.
Results
Patient characteristics
In total, we included 1276 CD patients in our 
study. At baseline, 669 (52.4%) patients pre-
sented with B1 disease, 248 (19.4%) patients 
with B2 and 359 (28.1%) patients with B3 
Table 1. Characteristics at baseline for the 1276 patients with clinical and 
genetic information.
Gender
 Male 628 (49.2%)
 Female 648 (50.8%)
Age
 Median, q25–q75, min–max 37.8, 26.1–50.3, 16.2–85.5
Stenosis 425 (33.3%)
Non-perianal fistula 171 (13.4%)
Perianal fistula 245 (19.2%)
Behavior
 B1 669 (52.4%)
 B2 (stenosis but no fistula) 248 (19.4%)
 B3 (fistula) 359 (28.1%)
Follow-up time (years)
 Median, q25–q75, min–max 6.8, 3.6–9.1, 0–11.6
Ronald Rentsch; Sophie 
Restellini; Jean-Pierre 
Richterich; Sylvia Rihs; 
Marc Alain Ritz; Jocelyn 
Roduit; Daniela Rogler; 
Gerhard Rogler; Jean-
Benoît Rossel; Markus 
Sagmeister; Gaby Saner; 
Bernhard Sauter; Mikael 
Sawatzki; Michela 
Schäppi; Michael Scharl; 
Martin Schelling; Susanne 
Schibli; Hugo Schlauri; 
Sybille Schmid Uebelhart; 
Jean-François Schnegg; 
Alain Schoepfer; Frank 
Seibold; Mariam Seirafi; 
Gian-Marco Semadeni; 
David Semela; Arne 






Alex Straumann; Bigna 
Straumann-Funk; Michael 
Sulz; Joël Thorens;; 
Radu Tutuian; Stephan 
Vavricka; Francesco Viani; 
Jürg Vögtlin; Roland Von 
Känel; Alain Vonlaufen; 
Dominique Vouillamoz; 
Rachel Vulliamy; Jürg 
Wermuth; Helene 
Werner; Paul Wiesel; 
Reiner Wiest; Tina Wylie; 
Jonas Zeitz; Dorothee 
Zimmermann
Therapeutic Advances in Gastroenterology 13
4 journals.sagepub.com/home/tag
according to the Montreal classification. Patient 
characteristics are given in Table 1.
Baseline probabilities for B stage migration 
during disease course
The dynamics of the model were summarized with 
transition intensities representing the instantaneous 
probability of switching from state to state. Those 
“baseline” intensities (with 95% CI) were: q = 0.033 
(0.027–0.039) to switch from B1 to B2; q = 0.016 
(0.012–0.021) to switch from B1 to B3 and 
q = 0.016 (0.011–0.023) to switch from B2 to B3. 
This means that there was twice as much “proba-
bility” for a patient to develop a stenosis than a fis-
tula during the disease course. In contrast, the 
probability of developing a fistula was similar, if 
already a stenosis was present or not. Detailed 
probabilities over the entire observation period are 
given in Table 2. The probability that a patient 
developed a stenosis is increased in the first year, 
while the probability that a patient developed a fis-
tula rose after 1 and 5 years of disease, respectively. 
In other words, the number of patients transform-
ing into B2 and into B3 disease increased over time. 
After 15 years, about 22% of patients were suffering 
from penetrating disease and more than 30% suf-
fered from stricturing disease (Figure 1).
Specific SNPs promote the transition intensities
In the next step, we analyzed the impact of genetic 
information/variation by calculating the transition 
intensities for each SNP. Using our linear mode-
ling approach, we identified nine out of 160 SNPs 
being significantly associated with B-stage pro-
gression (Table 3). The minor allele frequency of 
these SNPs in the European ancestry population 
as well as the GWAS significance of those nine 
SNPs is displayed in Supplemental Tables 1 and 
2. We next studied the number of relevant risk 
alleles identified with the linear modeling being 
present in each individual patient. We found that 
out of the 18 possible risk alleles (originating from 
homozygous or heterozygous presence of the nine 
significant SNPs), more than 20% of the patients 
had 11 risk alleles or more, while only a minority 
had less than eight risk alleles. The median num-
ber of risk alleles per patient was 11 (IQR 10–12), 
the minimum per patients 0 and the maximum 
number of risk alleles per patient was 17 (Figure 2).
Effects of single SNPs on disease course of CD 
patients in the linear modeling
We next investigated the impact of the presence of 
single SNPs for the disease course of CD patients 
in our linear modeling (Table 4, Supplemental 
Table 3, Supplemental Figure 1). The presence of 
SNP rs11010067 is highly unfavorable for CD 
Table 2. “Baseline” probabilities (with 95% CI) to develop a certain disease state.
Transition After 1 year After 5 years After 10 years
B1 to B1 (stay in B1) 0.952 (0.943–0.958) 0.780 (0.747–0.812) 0.608 (0.561–0.653)
B1 to B2 (stenosis but no fistula) 0.033 (0.027–0.039) 0.144 (0.119–0.171) 0.245 (0.206–0.285)
B1 to B3 (fistula) 0.016 (0.012–0.021) 0.076 (0.060–0.097) 0.147 (0.118–0.180)
B2 to B2 (stay in B2) 0.984 (0.978–0.990) 0.925 (0.891–0.948) 0.855 (0.800–0.896)
B2 to B3 (stenosis to fistula) 0.016 (0.010–0.022) 0.075 (0.052–0.109) 0.145 (0.104–0.200)
CI, confidence interval.
Figure 1. Phenotypic evolution of Crohn’s disease (CD) patients during their 
disease course.
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patients. Patients having one or two risk alleles have 
a greater risk of proceeding into a state with steno-
sis or fistula, with patients carrying two risk alleles 
being at the greatest risk for proceeding into a B3 
state. Patients carrying SNP rs1250546 are at par-
ticularly high risk of transition from B1 to B3. Of 
note, the presence of this SNP has no major role for 
progression to B2 stage, and even makes progres-
sion from B2 into B3 stage very unlikely (Table 4). 
Patients with SNP rs17229285 are protected from 
the onset of stenosis, but are at high risk of develop-
ing fistulas without stenosis. Patients carrying this 
SNP with stenosis are, however, unlikely to pro-
gress further into the B3 stage. The presence of 
SNP rs17694108 protects the patients from transi-
tion from B1 to B3 stage, however, clearly enhances 
the risk of developing fistula when already having a 
stenosis. Patients carrying SNP rs2066847 are pro-
tected from the onset of stenosis, but are at slightly 
increased risk of developing fistulas. The presence 
of SNPs rs2836878, rs4246905 and rs913678 
seems to be protective for CD patients, as it pre-
vents progression into B2 and also B3 stage. In 
contrast, patients carrying the SNP rs2945412 are 
generally at greater risk of developing stenosis and 
fistulas and are at particularly high risk of develop-
ing fistulas, when a stenosis is already present.
Effects of single SNPs on disease course of CD 
patients in the categorical modeling
We then performed the “categorical” effect 
model: The eight out of 160 SNPs that were 
detected as significantly associated with B-stage 
progression are presented in Table 5. For the cat-
egorical model, the impact of specific SNPs on 
disease course is given in Table 6 and Supplemental 
Table 4. The minor allele frequency of these SNPs 
in the European ancestry population as well as the 
GWAS significance of those nine SNPs is dis-
played in Supplemental Tables 1 and 2. Using this 
model, having two risk alleles of SNP rs11010067 
is specifically unfavorable for patients regarding 
the progression of B1 into B3 stage and also 
regarding the progression from B2 into B3 stage. 
With respect to the progression from B1 into B2 
Table 3. These SNPs have been detected as significant in the linear modeling.
Linear modeling Gene symbol Overall p value
Rs1250546 ZMIZ1 0.0004
Rs913678 CEBPB-PTPN1 0.0010
Rs11010067 No gene assigned 0.0086
Rs17229285 LOC105373831 0.0103
Rs2836878 No gene assigned 0.0139
Rs2066847 NOD2 0.0161
Rs17694108 No gene assigned 0.0233
Rs2945412 KSR1 0.0280
Rs4246905 TNFSF15 0.0422
SNP, single nucleotide polymorphism.
Figure 2. Distribution of the number of relevant risk alleles being present 
in one patient.
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stage, there is no difference whether one or two 
risk alleles are present. Patients carrying SNP 
rs11150589 are protected from progression from 
B1 into either B2 or B3 stage. However, carriers 
of this SNP are at higher risk of developing fistu-
las, when stenosis is already present. The pres-
ence of one or two risk alleles of SNP rs11230563 
is highly unfavorable for progression of B1 into 
B3 stage. In contrast, this SNP does not seem to 
play a major role for progression from B1 into B2 
or from B2 into B3 stage. Patients carrying SNP 
rs1363907 are generally protected from progres-
sion to a stricturing or penetrating disease pheno-
type. Carriers of SNP rs17229285 are at higher 
risk of developing fistulas directly from B1 stage, 
while the risk of developing a stenosis or fistulas 
when stenoses are present is only mildly elevated. 
Patients that carry the SNP rs2945412 are at 
highly elevated risk of developing stenosis, but 
also fistulas from either B1 or B2 stage. Patients 
carrying the SNP rs913678 are in general pro-
tected from the onset of stenosis or fistulas. With 
respect to SNP rs917997, patients are at higher 
risk of developing stenosis, but are protected from 
the onset of fistulas.
Discussion
In our study we aimed to identify genetic risk fac-
tors that might predict the progression of CD 
patients from an inflammatory disease state B1 to 
an either stricturing B2 and/or penetrating dis-
ease state B3. Identifying such risk factors at the 
time of initial diagnosis might help in the decision 
to start with a more aggressive initial therapy to 
prevent disease complications. It has already been 
shown that in CD patients the early administra-
tion of anti-TNF antibody treatment can poten-
tially prevent the disease progression towards a 
penetrating, but not a stricturing phenotype.9
Our data are in accordance with previous findings 
regarding the progression of CD patients towards 
structuring or penetrating complications during 
their disease course. We found that the majority 
of CD patients will eventually develop strictures/
stenosis or penetrating complications. The per-
centage of patients that progresses during their 
life-time are comparable to previous studies.4,26,27 
In particular, Cosnes et al. demonstrated in their 
long-term observational study that the transition 
of CD patients over a 5-year period from inflam-
matory B1 to structuring B2, and/or penetrating 
B3 complications occurs in 10% or, respectively, 
Table 4. The following SNPs exhibit significant 
transition intensities in the linear modeling.
Transition intensities HR (95% CI)
Rs 11010067
B1 to B2 1.338 (1.020–1.754)
B1 to B3 1.678 (1.132–2.487)
B2 to B3 1.234 (0.709–2.147)
Rs 1250546
B1 to B2 1.020 (0.768–1.356)
B1 to B3 2.313 (1.413–3.787)
B2 to B3 0.525 (0.308–0.897)
Rs 17229285
B1 to B2 0.729 (0.554–0.958)
B1 to B3 1.587 (1.049–2.393)
B2 to B3 0.730 (0.434–1.228)
Rs 17694108
B1 to B2 1.026 (0.771–1.364)
B1 to B3 0.489 (0.289–0.830)
B2 to B3 1.363 (0.786–2.362)
Rs 2066847
B1 to B2 0.513 (0.355–0.741)
B1 to B3 1.205 (0.506–2.871)
B2 to B3 1.052 (0.454–2.437)
Rs 2836878
B1 to B2 0.792 (0.591–1.063)
B1 to B3 0.570 (0.378–0.860)
B2 to B3 0.721 (0.418–1.244)
Rs 2945412
B1 to B2 1.271 (0.940–1.719)
B1 to B3 1.568 (0.991–2.482)
B2 to B3 1.606 (0.858–3.006)
Rs 4246905
B1 to B2 0.691 (0.515–0.928)
B1 to B3 0.794 (0.509–1.238)
B2 to B3 0.713 (0.409–1.243)
Rs 913678
B1 to B2 0.696 (0.523–0.926)
B1 to B3 0.557 (0.368–0.842)
B2 to B3 0.554 (0.388–1.135)
CI, confidence interval; SNP, single nucleotide 
polymorphism.
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26% of CD patients.4 Nevertheless, although 
some more recent data have shown that a smaller 
fraction of CD patients might change their dis-
ease behavior during the disease course,6–8,28 fur-
ther studies are not supporting this observation.9
We found that from a total of 162 analyzed SNPs 
there were only a few SNPs associated with a high 
risk of disease progression from stage B1 into 
either stage B2 or B3 (e.g. rs11010067, 
rs1250546, rs2945412, rs11230563, rs917997) 
or solely into stage B3 (rs17229285) or B2 
(rs17694108). This suggests that the disease 
course in CD patients is not only determined by 
genetics, but is also influenced by other patient 
characteristics. In line with this, the genetic 
impact on disease development in IBD patients 
has previously been estimated to constitute only 
about 25%.16,29,30
Stricturing disease was in previous studies found 
to be associated with ASCA, CBir1 and GM-CSF 
seropositivity, while penetrating disease was asso-
ciated also with ASCA and CBir1, but not 
GM-CSF seropositivity.31 The three gene loci 
NOD2, major histocompatibility complex (MHC) 
and 3p21 (MST1) were previously found to be 
strongly associated with CD. Moreover, NOD2 is 
associated with penetrating, but not with strictur-
ing disease.16 In-depth analysis of the MHC region 
showed that the strongest signals for disease loca-
tion were associations with HLA-DRB1*01:03, 
HLS-DRB1*07:01 and SNP rs77005575.16
Previous studies already described a role for a 
number of SNPs located within the TNFSF15 
gene locus as being associated with disease pro-
gression in CD patients.13,32 In our paper we 
identified a further SNP within this gene locus, 
namely SNP rs4246905, to protect from disease 
progression, confirming the role of TNFSF15 in 
this regard. On a functional level, TNFSF15, also 
known as TL1A, and its receptor DR3 have been 
shown to be widely expressed in inflamed intes-
tinal tissue of IBD patients.33 TNFSF15 has 
been shown to exert a dual role in intestinal 
immunity. Via its involvement in innate immune 
responses, it plays a protective role for the intes-
tinal mucosa by ameliorating inflammatory 
responses and promoting wound healing during 
acute inflammation. However, TNFSF15 also 
exerts pro-inflammatory effects primarily by 
modulating T-cell and innate lymphoid cell acti-
vation via its role in adaptive immunity.34 Further 
data have suggested that TNFSF15 might be a 
critical mediator of intestinal fibrosis, dependent 
on the intestinal microbiota, and suggested that 
targeting TNFSF15 might be a plausible approach 
for the treatment of CD and other inflammatory 
diseases.35,36 Further studies are needed to eluci-
date such potential pathogenetic mechanisms and 
therapeutic potentials in more detail. Such 
improved molecular understanding might then 
finally guide therapy in CD patients at initial CD 
diagnosis and propose a less aggressive first-line 
therapy leading to fewer side effects and finally to 
improved quality of life.
Table 5. These SNPs have been detected as significant in the categorical modeling.
Categorical modeling Gene symbol Overall p value
Rs913678 CEBPB-PTPN1 0.0036
Rs11010067 No gene assigned 0.0369
Rs17229285 LOC105373831 0.0030
Rs11230563 CD6 0.0356




SNP, single nucleotide polymorphism.
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Table 6. The following SNPs exhibit significant transition intensities in the categorical modeling.
Transition intensities HR (95% CI)
For 1 risk allele
HR (95% CI)
For 2 risk alleles
Rs 11010067
B1 to B2 1.662 (1.070–2.581) 1.665 (0.921–3.010)
B1 to B3 1.815 (0.913–3.605) 2.807 (1.257–6.267)
B2 to B3 1.134 (0.508–2.530) 1.610 (0.513–5.055)
Rs 11150589
B1 to B2 0.822 (0.516–1.311) 1.643 (0.998–2.703)
B1 to B3 0.678 (0.365–1.258) 0.664 (0.289–1.526)
B2 to B3 1.143 (0.514–2.544) 0.401 (0.514–1.456)
Rs 11230563
B1 to B2 1.032 (0.586–1.820) 0.579 (0.310–1.079)
B1 to B3 3.977 (0.854–18.506) 3.029 (0.637–14.407)
B2 to B3 0.985 (0.327–2.968) 0.641 (0.197–2.080)
Rs 1363907
B1 to B2 0.822 (0.523–1.292) 1.645 (0.992–2.727)
B1 to B3 0.717 (0.378–1.362) 1.218 (0.570–2.605)
B2 to B3 0.382 (0.164–0.894) 0.536 (0.179–1.603)
Rs 17229285
B1 to B2 1.071 (0.685–1.676) 0.453 (0.238–0.860)
B1 to B3 2.970 (1.056–8.353) 3.401 (1.162–9.954)
B2 to B3 1.014 (0.435–2.366) 0.458 (0.138–1.520)
Rs 2945412
B1 to B2 3.568 (1.415–9.000) 2.985 (1.778–7.564)
B1 to B3 1.525 (0.496–4.685) 2.418 (0.828–4.685)
B2 to B3 1.267 (0.274–5.860) 2.226 (0.509–9.733)
Rs 913678
B1 to B2 0.826 (0.459–1.487) 0.517 (0.278–0.965)
B1 to B3 0.328 (0.160–0.672) 0.286 (0.137–0.599)
B2 to B3 0.679 (0.245–1.884) 0.448 (0.150–1.337)
Rs 917997
B1 to B2 1.536 (1.028–2.295) 1.122 (0.505–2.492)
B1 to B3 0.691 (0.355–1.345) 2.654 (1.262–5.580)
B2 to B3 0.905 (0.402–2.036) 2.315 (0.763–7.030)
CI, confidence interval; HR, hazard ratio; SNP, single nucleotide polymorphism.
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Interestingly, we found that the protective or det-
rimental effect of certain SNPs depends on the 
number of risk alleles being present in one patient, 
for example, rs11150589 located on the gene 
locus encoding Integrin alpha L (ItgaL) or 
rs1363907 located on gene locus encoding endo-
plasmic reticulum aminopeptidases (ERAP) 1 
and 2. At a functional level, ItgaL is involved in 
immune cell adhesion,37 ERAP1 and 2 are 
involved in cell surface cleavage of cytokine recep-
tors and antigen processing that suggests an 
important role in inflammation.38 This observa-
tion demonstrates that also the number of risk 
alleles is critical for the development of the dis-
ease course and shows that the gene–host–disease 
interplay is highly complex and, to date, still not 
well understood.
Overall, we tested 160 SNPs available in the 
SIBDCS and we found more or less 5% of signifi-
cant ones, as one could expect. This is a higher 
number of relevant SNPs than, for example, 
Cleynen et al. detected in their large study from 
2016.16 We are fully aware that genetics cannot 
explain the disease progression, but it is still inter-
esting to find which SNPs might be the most 
important ones, according to our data.
It is also interesting to note that we “only” found 
eight or nine significant SNPs, despite our quite 
large sample size of 1276 patients. Although we 
have presented evidence that our findings point 
towards a possible role for the detected variants in 
disease progression, we stress that none survives 
multiple testing correction and hence better pow-
ered studies are needed to confirm the bona fide 
nature of each individual association.
Of note, adjustment for specific factors is impor-
tant for such a study as we performed. Our results 
indeed are adjusted for disease duration. In our 
previous publication studying the very same 
patient collective from the SIBDCS,39 we found 
by multivariate testing, the hazard ratio for migrat-
ing from B1 to pB3 (HR 0.27) and from B2 to 
pB3 (HR 0.12) was lower in patients >40 years 
compared to patients <17 years. In this study, we 
additionally found that immunosuppression (HR 
0.38) and treatment with anti-TNF for >1 year 
(HR 0.30) were associated with a decreased likeli-
hood of transitioning from stage B1 to pB3.39
A limitation of our study is, however, that our 
SNPs analyzed apply to patients living in 
Switzerland. While different ethnicities might 
be present in the cohort, the majority consists 
of a Caucasian race. It would be important and 
interesting to expand the study and to examine 
if our SNP results can be verified in patient col-
lectives including other ethnicities. Further, it 
must be mentioned that we tried to exemplarily 
perform a multivariate model with all SNPs 
mentioned in Table 4. However, the coeffi-
cients did not convincingly change, which is 
due to the fact that correlations between SNPs 
are quite low.
In summary, within our study we identified novel 
associations between SNPs in CD risk genes and 
the disease course in CD patients. Notably, we 
found genetic variations that confer increased or 
decreased risk for disease progression. However, 
we also demonstrated that developing a stenosis is 
not a prerequisite for progressing to B3 state. The 
validation of those genetic associations and an 
improved molecular understanding about the func-
tional role in CD pathogenesis might finally result 
in the identification of predictive biomarkers that 
could help in first-line therapy decision-making.
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